Securities code:603520
Development milestones
Zhejiang Starry Pharmaceutical Co., Ltd. was founded in 1997.
Company Incorporation
1997Changed name to"Zhejiang starry Pharmaceutical Co., Ltd."
2003Modern medical chemical base put into operation
2008Jiangxi Starry Pharmaceutical Co., Ltd. was established
2011Shanghai Starry Pharmaceutical Co., Ltd. was established
2012Landed in the Chinese A-stock market, Stock code 603520
2016Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. was merged into Starry
2019Shanghai Starry achieved commercial production of FDF
2020Won in fifth national centralized bidding
2021Won in seventh national centralized bidding
2022Implement API+FDF global promotion strategy
2023-2026Starry has been established for over 20 years
2023-2026
Implement API+FDF global promotion strategy
2022
Won in seventh national centralized bidding
2021
Won in fifth national centralized bidding
2020
Shanghai Starry achieved commercial production of FDF
2019
Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. was merged into Starry
2016
Landed in the Chinese A-stock market, Stock code 603520
2012
Shanghai Starry Pharmaceutical Co., Ltd. was established
2011
Jiangxi Starry Pharmaceutical Co., Ltd. was established
2008
Modern medical chemical base put into operation
2003
Changed name to"Zhejiang starry Pharmaceutical Co., Ltd."
1997
Company Incorporation
Starry has been established for over 20 years
development path
2023-2026
Implement API+FDF global promotion strategy
2022
Won in seventh national centralized bidding
2021
Won in fifth national centralized bidding
2020
Shanghai Starry achieved commercial production of FDF
2019
Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. was merged into Starry
2016
Landed in the Chinese A-stock market, Stock code 603520
2012
Shanghai Starry Pharmaceutical Co., Ltd. was established
2011
Jiangxi Starry Pharmaceutical Co., Ltd. was established
2008
Modern medical chemical base put into operation
2003
Changed name to"Zhejiang starry Pharmaceutical Co., Ltd."
1997
Company Incorporation
2023-2026
Implement API+FDF global promotion strategy
2022
Won in seventh national centralized bidding
2021
Won in fifth national centralized bidding
2020
Shanghai Starry achieved commercial production of FDF
2019
Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd. was merged into Starry
2016
Landed in the Chinese A-stock market, Stock code 603520
2012
Shanghai Starry Pharmaceutical Co., Ltd. was established
2011
Jiangxi Starry Pharmaceutical Co., Ltd. was established
2008
Modern medical chemical base put into operation
2003
Changed name to"Zhejiang starry Pharmaceutical Co., Ltd."
1997
Company Incorporation
Copyright © Zhejiang Starry Pharmaceutical Co., Ltd. All Rights Reserved.
Powered by www.300.cn
Wap
CONTACT US
Tel: 0576-87718628 / 021-37916067
E-mail: sales@starrypharma.com
Zhejiang Starry Pharmaceutical Co., Ltd.
Add: No.l Starry Road of Xianju, Modern IndustriaL, Centralization Zone, Xianju, Zhejiang, China
Shanghai Starry Pharmaceutical Co., Ltd.
Add: No.500 Maoye Road,Jinshan District 201506, Shanghai city, China
Zhejiang Taizhou Hisyn Pharmaceutical Co., Ltd.
Add: Chemical and Medical Raw Materials Base, Linhai Park, Zhejiang, China
Jiangxi Starry Pharmaceutical Co., Ltd.
Add: North of the Wuyl Road,Salt chemical Base, Zhangshu, Jiangxi, 331200, P.R.China
Imax Diagnostic Imaging Limited
Add: Phoenix House, Room 137 Monahan Road, CorkT12H1XY Republic of lreland
E-mail:info@imaxdiagnostic.com
Tel: 00353 21 451 9990
REQUEST A QUOTE